Silymarin inhibits the lipogenic pathway and reduces worsening of non-alcoholic fatty liver disease (NAFLD) in mice.

Autor:	Carvalho LCF; Laboratório de Bioquímica Metabólica, Universidade Federal de Ouro Preto, Ouro Preto, Brazil., Ferreira FM; Laboratório de Bioquímica Metabólica, Universidade Federal de Ouro Preto, Ouro Preto, Brazil., Dias BV; Laboratório de Bioquímica Metabólica, Universidade Federal de Ouro Preto, Ouro Preto, Brazil., Azevedo DC; Laboratório de Bioquímica Metabólica, Universidade Federal de Ouro Preto, Ouro Preto, Brazil., de Souza GHB; Laboratório de Fitotecnologia, Universidade Federal de Ouro Preto, UFOP, Ouro Preto, Brazil., Milagre MM; Laboratório Doença de Chagas, Universidade Federal de Ouro Preto, UFOP, Ouro Preto, Brazil., de Lana M; Laboratório Doença de Chagas, Universidade Federal de Ouro Preto, UFOP, Ouro Preto, Brazil., Vieira PMA; Laboratório de Morfopatologia, Universidade Federal de Ouro Preto, UFOP, Ouro Preto, Brazil., Carneiro CM; Laboratório de Imunopatologia, Universidade Federal de Ouro Preto UFOP, Ouro Preto, Brazil., Paula-Gomes S; Laboratório de Bioquímica e Biologia Molecular, Universidade Federal de Ouro Preto, UFOP, Ouro Preto, Brazil., Cangussu SD; Laboratório de Fisiopatologia Experimental, Universidade Federal de Ouro Preto, UFOP, Ouro Preto, Brazil., Costa DC; Laboratório de Bioquímica Metabólica, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
Jazyk:	angličtina
Zdroj:	Archives of physiology and biochemistry [Arch Physiol Biochem] 2024 Aug; Vol. 130 (4), pp. 460-474. Date of Electronic Publication: 2022 Nov 03.
DOI:	10.1080/13813455.2022.2138445
Abstrakt:	Context: The role of silymarin in hepatic lipid dysfunction and its possible mechanisms of action were investigated. Objective: To evaluate the effects of silymarin on hepatic and metabolic profiles in mice fed with 30% fructose for 8 weeks. Methods: We evaluated the antioxidant profile of silymarin; mice consumed 30% fructose and were treated with silymarin (120   mg/kg/day or 240 mg/kg/day). We performed biochemical, redox status, and histopathological assays. RT-qPCR was performed to detect ACC-1, ACC-2, FAS, and CS expression, and western blotting to detect PGC-1α levels. Results: Silymarin contains high levels of phenolic compounds and flavonoids and exhibited significant antioxidant capacity in vitro. In vivo , the fructose-fed groups showed increased levels of AST, ALT, SOD/CAT, TBARS, hepatic TG, and cholesterol, as well as hypertriglyceridaemia, hypercholesterolaemia, and increased ACC-1 and FAS. Silymarin treatment reduced these parameters and increased mRNA levels and activity of hepatic citrate synthase. Conclusions: These results suggest that silymarin reduces worsening of NAFLD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu